Sandoz: raises growth forecast for 2024
(CercleFinance.com) - On its H1 publication, Sandoz announces that it has raised its revenue growth forecast to mid-to-high single-digits at constant exchange rates, and is more confident in achieving a core EBITDA margin of around 20%.
In H1 2024, the Swiss generics and biosimilars manufacturer's core EBITDA margin improved 2.1% to 17.5%, on revenues that rose 6% to $5.05bn (+7% at constant exchange rates).
"We expect momentum in our business to continue in the second half of the year, with margin expansion coming from favorable product mix, leveraging expenses on growing topline, and contribution from our transformation program", says CEO Richard Saynor.
Sandoz also announces the appointments to its Executive Committee of Rebecca Guntern as Chief Commercial Officer, and Christophe Delenta as President Europe, both effective 1 September.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
In H1 2024, the Swiss generics and biosimilars manufacturer's core EBITDA margin improved 2.1% to 17.5%, on revenues that rose 6% to $5.05bn (+7% at constant exchange rates).
"We expect momentum in our business to continue in the second half of the year, with margin expansion coming from favorable product mix, leveraging expenses on growing topline, and contribution from our transformation program", says CEO Richard Saynor.
Sandoz also announces the appointments to its Executive Committee of Rebecca Guntern as Chief Commercial Officer, and Christophe Delenta as President Europe, both effective 1 September.
Copyright (c) 2024 CercleFinance.com. All rights reserved.